Philadelphia Lung Cancer Symposium
Join us for the Philadelphia Lung Cancer Symposium, a dynamic, multidisciplinary education program featuring expert faculty from leading Philadelphia institutions, hosted by Fox Chase Cancer Center (FCCC) in collaboration with Penn Medicine’s Abramson Cancer Center. This full-day symposium—led by Program Directors Hossein Borghaei, DO, MS (FCCC) and Charu Aggarwal, MD, MS (Abramson Cancer Center)—delivers a high-impact review of evolving standards in early-stage disease, small cell lung cancer, targeted therapies, and emerging approaches shaping practice in 2026 and beyond.
Focused presentations, surgical and radiation perspectives, and interactive case-based discussions will provide practical insight into perioperative strategies, biomarker-driven treatment selection, emerging therapeutics, and real-world multidisciplinary decision-making. Attendees will leave with clear, actionable updates to apply in clinical practice.
DATE:
Saturday, October 17, 2026
TIMES:
7:30 AM – 8:00 AM Check-in & Breakfast
8:00 AM – 4:00 PM Education Program
LOCATION:
Philadelphia Marriott Old City
One Dock Street
Philadelphia, PA 19106
PROGRAM DIRECTORS:
Hossein Borghaei, DO, MS
Interim Chair & Professor, Department of Hematology/Oncology;
Chief, Division of Thoracic Medical Oncology;
Co-Director, Immune Monitoring Facility;
Gloria and Edmund M. Dunn Chair in Thoracic Oncology,
Fox Chase Cancer Center
Charu Aggarwal, MD, MS
Section Chief, Head & Neck and Thoracic Cancers, Hematology/Oncology;
Director, Precision Oncology Innovation, Penn Center for Cancer Care Innovation;
Physician Leader, Airways Malignancies Research;
Leslye M. Heisler Professor for Lung Cancer Excellence,
Penn Medicine’s Abramson Cancer Center
TOPICS
- Recent Advances in Lung Cancer Treatment
- Biomarker-Driven Care
- HER2 Testing and HER2-Directed Therapies
- Targeted Therapies
- Bispecific Antibodies in Lung Cancer Care
- Early-Stage Disease
- Perioperative Strategies
- Small Cell Lung Cancer
- Emerging Therapeutics
LEARNING OBJECTIVES
By the end of this program, learners will be able to:
- Provide an update on the most recent changes in the treatment of lung cancer
- Explain the rationale and need for HER2 testing and HER2-directed treatment
- Describe the use of bispecific antibodies in lung cancer treatment
AUDIENCE
- Physicians and Trainees
- Nurses
- Advanced Practice Providers
- Rehabilitation Specialists and Genetic Counselors
- Pharmacy, Radiology, and Pathology Professionals
- Patient Navigators and Other Healthcare Professionals Involved in Lung Cancer Care
WHAT YOU’LL GAIN FROM ATTEDNING
- Updates on the latest advances in lung cancer treatment and evolving standards of care
- Practical strategies for perioperative management and biomarker-driven treatment selection
- Multidisciplinary perspectives on real-world challenges and collaborative decision-making
- Tools and best practices you can apply immediately in clinical practice
ACCREDITATION STATEMENT:
The Temple Health Office for Continuing Medical Education is accredited by the Pennsylvania Medical Society to provide continuing medical education for physicians. Fox Chase Cancer Center is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
DESIGNATION STATEMENT:
The Temple Health Office for Continuing Medical Education designates this live activity for a maximum of 6 AMA PRA Category 1 Credits™. Physicians should only claim the credit commensurate with the extent of their participation in the educational activity.
Fox Chase Cancer Center designates this live activity for a maximum of 6 Hour(s) NCPD (ANCC Contact Hours). Participants should claim only the credit commensurate with the extent of their participation in the activity.
INQUIRIES: